Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.

Clinical and translational science - 1 Jul 2026

Huth Felix, Shakeri-Nejad Kasra, Gardin Anne, Shah Bharti, Pohl Oliver, Pezous Nicole, Faller Thomas

Abstract excerpt

Multiple sclerosis (MS) is a significant cause of neurological disability in young adults. Siponimod, a potent sphingosine-1-phosphate (S1P) receptor modulator, is used to treat MS by reducing T-cell recirculation and central inflammation. The presented work includes clinical data describing the impact of the CYP3A4 inhibitor clarithromycin on siponimod metabolism and the results of updated physiologically based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Azetidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzyl Compounds

Share to Clarithromycin

Share to Cytochrome P-450 CYP2C9

Share to Cytochrome P-450 CYP3A Inhibitors

Share to Drug Interactions

Share to Healthy Volunteers

Source

Open in PubMed Open full text

Identifiers

PMID: 42364973
DOI: 10.1111/cts.70657
PMCID: PMC13310184

Genes

CYP2C9
CYP3A4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.PMID 42364973Read ↗

Pharmacogenetics of siponimod: A systematic review.Semantic proximity Read ↗

The Impact of Sphinogosine-1-Phosphate Receptor Modulators on COVID-19 and SARS-CoV-2 VaccinationSemantic proximity Read ↗

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.Semantic proximity Read ↗

A PBPK Digital Twin of Rapamycin for Predicting Dose–Exposure Relationships, Organ Impairment Effects, and Drug–Drug InteractionsSemantic proximity Read ↗

Implications for multiple sclerosis in the era of the Affordable Care Act: an evolving treatment paradigm.Semantic proximity Read ↗

Population pharmacokinetic modeling and Monte Carlo simulation-based dosing optimization of trimethoprim-sulfamethoxazole in critically ill patients.Semantic proximity Read ↗

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.Semantic proximity Read ↗

Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations.Semantic proximity Read ↗

Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.Semantic proximity Read ↗

Pharmacokinetic Drug-Drug Interactions of DA-8010 with Clarithromycin or Rifampicin: Influence of CYP2D6 Phenotype on the Extent of These Interactions.Semantic proximity Read ↗

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.Semantic proximity Read ↗

PBPK Modeling of Esomeprazole to Support Adolescent Pharmacokinetic Extrapolation and Label Extension in Chinese Patients With Gastroesophageal Reflux Disease (GERD).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.